Blog

Dr. Nawaid Usmani and team receive funding for their PRIME study!

The PRIME Study – Prevention and Intervention for MEtabolic syndrome:

Androgen deprivation therapy (ADT), and newer manipulations of androgen receptor signaling have improved outcomes for advanced prostate cancer (PCa) patients.  The toxicities of ADT are many, including an increased risk of developing metabolic syndrome (MS; defined as at least 3 of: hyperglycemia; abdominal obesity; hypertriglyceridemia; reduced HDL cholesterol; and/or hypertension). MS is associated with an increased risk of diabetes, cardiovascular disease mortality, stroke mortality, and all-cause mortality.  The prevalence of MS in men receiving ADT is at least 50% and contributes to decreased quality of life and increased non-cancer-related mortality.  Metformin holds promise as a countermeasure to MS development, and also has been shown to suppress PCa growth in pre-clinical models.

We hypothesize that the addition of metformin to ADT will reduce the rates of MS in men with advanced PCa, diminishing important toxicities of a therapy universally used in advanced disease.

We propose a double-blind, randomized phase III study of metformin or placebo in men with PCa starting intermittent ADT. The primary endpoint is the difference in MS rates at 1 year.  Other aims include evaluation of the influence of metformin on: individual MS components at additional time points; mean serum insulin levels and measures of insulin resistance; weight and quality of life.

A finding that metformin reduces MS incidence and/or has other benefits would change practice, as it would provide a practical and inexpensive strategy to reduce toxicity of an intervention employed in most men with advanced PCa.

Stay Informed

To stay up to date on all the latest news and publications, subscribe to our newsletter!

Recent Posts

15th Annual Personalized Medicine Conference Posted on Nov 9 19 at 5:14pm
Evaluating the measurement properties of EPIC-26 Posted on Nov 6 19 at 12:19pm
APCaRI 2019 Fall Symposium Posted on Oct 22 19 at 12:28pm

Annual Terwillegar Trail Run and Walk Fundraiser

It was a beautiful crisp fall morning for a 10 Km trail run or 7.5 Km walk through the Terwillegar ravine on Saturday, September 29th. The run/walk, hosted by the Terwillegar Trail Run/Walk and the Alberta Cancer Foundation,  is in its 7th year. Its goal is to bring families and friends together to enjoy the outdoors and ultimately raise funds for prostate cancer research.

John Lewis’ research group was out in force; represented by John Lewis, Catalina Vasquez, Arun Raturi, Perrin Beatty and Abbie Coros. Despite the fact that, as one of the run/walk organizers Doug Mitchell pointed out to the participants, John ran in 15-year-old tennis shoes, the Lewis group runners ran well and had a great time!

Funds raised by the Terwillegar Trail Run and Walk go to support cancer research in Alberta. Check out the Alberta Cancer Foundations’ “Dollars at Work” to read about how these funds have been used to support the research from APCaRI members Dr. Frank Wuest and Dr. John Lewis’ labs!

With just over 100 participants this year the 2018 Terwillegar Trail Run/Walk raised over $21 000 for prostate cancer research! You can still donate to this awesome fundraiser, just go to Alberta Cancer Foundation TTRW and click on the Donate Now button!

- Perrin Beatty